Depletion of CD38-positive regulatory T cells by anti-CD38 monoclonal antibodies induces a durable response to SARS-CoV-2 vaccination in patients with plasma cell dyscrasia

Toshiki Terao, Takashi Naduka, Daisuke Ikeda, Ami Fukumoto, Yuya Kamura, Ayumi Kuzume, Rikako Tabata, Takafumi Tsushima, Daisuke Miura, Kentaro Narita, Masami Takeuchi, Kosei Matsue

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

This study reports the relationship between CD38+ regulatory T cells (Tregs) and messenger RNA coronavirus disease 2019 (mRNA-COVID-19) vaccination in 60 patients with plasma cell dyscrasia. Patients treated with anti-CD38 monoclonal antibodies (mAbs) had significantly lower CD38+ Tregs than those not treated (0.9 vs. 13.2/μl). Late-responders, whose antibody titres increased from weeks 4–12 after the second vaccination, had significantly lower CD38+ Treg counts than non-late-responders (2.5 vs. 10.3/μl). Antibody titres in patients with lower CD38+ Treg levels were maintained from weeks 4–12 but decreased in those with higher CD38+ Treg levels. Therefore, depletion of CD38+ Tregs by anti-CD38 mAbs may induce a durable response to mRNA-COVID-19 vaccination.

Original languageEnglish
Pages (from-to)417-421
Number of pages5
JournalBritish Journal of Haematology
Volume197
Issue number4
DOIs
Publication statusPublished - May 2022
Externally publishedYes

Keywords

  • anti-CD38 monoclonal antibody
  • coronavirus disease 2019 (COVID-19)
  • multiple myeloma
  • regulatory T cell
  • vaccines

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Depletion of CD38-positive regulatory T cells by anti-CD38 monoclonal antibodies induces a durable response to SARS-CoV-2 vaccination in patients with plasma cell dyscrasia'. Together they form a unique fingerprint.

Cite this